Innova and TGR Enter Co-Marketing Agreement for Complementary Core Biotechnologies
|
By LabMedica International staff writers Posted on 02 Feb 2014 |
Combining ELISA technology from TGR BioSciences (Adelaide, Australia) with conjugation kits from Innova Biosciences (Cambridge, UK) improves ELISA sensitivity and reduces cost.
TGR develops rapid, high sensitivity ELISA systems using their CaptSure technology, and Innova provides superior bioconjugation systems. Having entered into the agreement to promote and co-market their highly complementary technologies, they can now provide customers with a major step forward in simplifying a laboratory's ELISA development process, while improving sensitivity and reducing costs.
TGR has determined that combining Innova’s "Lightning-Link" conjugation kits for the horseradish peroxidase (HRP) labeling of antibodies with its "CaptSure" technology enables rapid and cost-effective development of a wide range of high sensitivity ELISA assays. As part of the agreement, Innova customers will be introduced to the CaptSure technology as providing added value when used alongside Lightning-Link reagents. Similarly, Lightning-Link will be introduced to TGR customers with a recommendation of the added value when used alongside CaptSure products.
TGR’s CaptSure technology simplifies ELISA assays to one-step procedures, making them much faster and easier to carry out. Both assay antibodies are added to analyte at once, and after a single wash step, the HRP substrate is added to develop the signal. Importantly, manufacture and environmental costs are greatly reduced, since only a single assay plate is required (coated with CaptSure reagent) rather than a different plate for each target and the system requires much lower amounts of assay antibodies. Innova’s Lightning-Link conjugation system provides the ability to label antibodies with only 30 seconds hands-on time, while offering 100% yields and enhanced sensitivity over traditional labeling techniques and over other conjugation systems on the market.
“We’ve been impressed with Innova’s products. Their HRP conjugation kit is simple to use and at the same time provides performance that exceeds that of a range of other systems that we have tested. We are very happy to recommend Lightning-Link to anyone who is developing assays with our CaptSure system,” said Dr. Michael Crouch, Director of Business Development at TGR. Dr. Andy Lane, Executive Director at Innova Biosciences, said, "We are pleased to further develop our relationship with TGR. Their CaptSure technology provides advantages in ELISA assay development that are directly complementary to the ethos of our conjugation technology—simplicity, high speed, and enhanced sensitivity.”
Related Links:
TGR BioSciences
Innova Biosciences
TGR develops rapid, high sensitivity ELISA systems using their CaptSure technology, and Innova provides superior bioconjugation systems. Having entered into the agreement to promote and co-market their highly complementary technologies, they can now provide customers with a major step forward in simplifying a laboratory's ELISA development process, while improving sensitivity and reducing costs.
TGR has determined that combining Innova’s "Lightning-Link" conjugation kits for the horseradish peroxidase (HRP) labeling of antibodies with its "CaptSure" technology enables rapid and cost-effective development of a wide range of high sensitivity ELISA assays. As part of the agreement, Innova customers will be introduced to the CaptSure technology as providing added value when used alongside Lightning-Link reagents. Similarly, Lightning-Link will be introduced to TGR customers with a recommendation of the added value when used alongside CaptSure products.
TGR’s CaptSure technology simplifies ELISA assays to one-step procedures, making them much faster and easier to carry out. Both assay antibodies are added to analyte at once, and after a single wash step, the HRP substrate is added to develop the signal. Importantly, manufacture and environmental costs are greatly reduced, since only a single assay plate is required (coated with CaptSure reagent) rather than a different plate for each target and the system requires much lower amounts of assay antibodies. Innova’s Lightning-Link conjugation system provides the ability to label antibodies with only 30 seconds hands-on time, while offering 100% yields and enhanced sensitivity over traditional labeling techniques and over other conjugation systems on the market.
“We’ve been impressed with Innova’s products. Their HRP conjugation kit is simple to use and at the same time provides performance that exceeds that of a range of other systems that we have tested. We are very happy to recommend Lightning-Link to anyone who is developing assays with our CaptSure system,” said Dr. Michael Crouch, Director of Business Development at TGR. Dr. Andy Lane, Executive Director at Innova Biosciences, said, "We are pleased to further develop our relationship with TGR. Their CaptSure technology provides advantages in ELISA assay development that are directly complementary to the ethos of our conjugation technology—simplicity, high speed, and enhanced sensitivity.”
Related Links:
TGR BioSciences
Innova Biosciences
Latest Industry News
- MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition
- Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
- Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
- QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
- WHX Labs in Dubai spotlights leadership skills shaping next-generation laboratories
- AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
- New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
- Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
- WHX Labs Dubai to Gather Global Experts in Antimicrobial Resistance at Inaugural AMR Leaders’ Summit
- BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
- Abbott Acquires Cancer-Screening Company Exact Sciences
- Roche and Freenome Collaborate to Develop Cancer Screening Tests
- Co-Diagnostics Forms New Business Unit to Develop AI-Powered Diagnostics
- Qiagen Acquires Single-Cell Omics Firm Parse Biosciences
- Puritan Medical Products Showcasing Innovation at AMP2025 in Boston
- Advanced Instruments Merged Under Nova Biomedical Name
Channels
Clinical Chemistry
view channel
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read more
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreMolecular Diagnostics
view channel
Blood Test Predicts Dementia in Women 25 Years Before Symptoms Begin
Dementia and Alzheimer’s disease often develop silently over many years before symptoms appear. Detecting risk earlier could allow preventive strategies to begin long before memory problems interfere with... Read more
Serial Liquid Biopsies Reveal Therapy Resistance in Metastatic Prostate Cancer
Metastatic Prostate cancer can rapidly adapt under treatment, making it difficult to detect resistance before clinical progression. Genomic results from archival tumor tissue may no longer reflect the... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more








